FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885393419> ?p ?o ?g. }

• W2885393419 endingPage "1743" @default.
• W2885393419 startingPage "1741" @default.
• W2885393419 abstract "Future Medicinal ChemistryVol. 10, No. 15 EditorialUSP14 inhibitors as potential anticancer agentsStina Lundgren & Ewa OdrzywolStina Lundgren*Author for correspondence: E-mail Address: stina.lundgren@medivir.se Medivir AB, Box 1086 Stockholm 111 48, SwedenSearch for more papers by this author & Ewa Odrzywol Medivir AB, Box 1086 Stockholm 111 48, SwedenSearch for more papers by this authorPublished Online:15 Aug 2018https://doi.org/10.4155/fmc-2018-0150AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancerDUBsinhibitorsUSP14References1 Huang X, Dixit VM. Drugging the undruggable: exploring the ubiquitin system for drug development. Cell Res. 26(4), 484–498 (2016).Crossref, Medline, CAS, Google Scholar2 de Poot SAH, Tian G, Finley D. Meddling with Fate: the proteasomal deubiquitinating enzymes. J. Mol. Biol. 429(22), 3525–3545 (2017).Crossref, Medline, CAS, Google Scholar3 Borodovsky A, Kessler BM, Casagrande R, Overkleeft HS, Wilkinson KD, Ploegh HL. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J. 20(18), 5187–5196 (2001).Crossref, Medline, CAS, Google Scholar4 Jung H, Kim BG, Han WH et al. Deubiquitination of Dishevelled by Usp14 is required for Wnt signaling. Oncogenesis 2, e64 (2013).Crossref, Medline, CAS, Google Scholar5 Xu D, Shan B, Sun H et al. USP14 regulates autophagy by suppressing K63 ubiquitination of Beclin 1. Genes Dev. 30(15), 1718–1730 (2016).Crossref, Medline, CAS, Google Scholar6 Lee BH, Lee MJ, Park S et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467(7312), 179–184 (2010).Crossref, Medline, CAS, Google Scholar7 Shinji S, Naito Z, Ishiwata S et al. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol. Rep. 15(3), 539–543 (2006).Medline, CAS, Google Scholar8 Wu N, Liu C, Bai C, Han Y-P, Cho WC, Li Q. Overexpression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin. Int. J. Mol. Sci. 14(6), 10749–10760 (2013).Crossref, Medline, Google Scholar9 Kemp M. Recent advances in the discovery of deubiquitinating enzyme inhibitors. Prog. Med. Chem. 55, 149–192 (2016).Crossref, Medline, Google Scholar10 D'Arcy P, Brnjic S, Olofsson MH et al. Inhibition of proteasome ubiquitinating activity as a new cancer therapy. Nat. Med. 17(12), 1636–1640 (2011).Crossref, Medline, Google Scholar11 Tian Z, D'Arcy P, Wang X et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123(5), 706–716 (2014).Crossref, Medline, CAS, Google Scholar12 Dimmock RJ, Padmanilayam MP, Puthucode RN et al. A conformational and structure−activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues. J. Med. Chem. 44(4), 586–593 (2001).Crossref, Medline, CAS, Google Scholar13 Wang X, D'Arcy P, Caulfield TR et al. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem. Biol. Drug Des. 86(5), 1036–1048 (2015).Crossref, Medline, CAS, Google Scholar14 US National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02372240.Google Scholar15 Chen X, Yang Q, Xiao L, Tang D, Dou QP, Liu J. Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents. Cancer Metastasis Rev. 36(4), 655–668 (2017).Crossref, Medline, CAS, Google Scholar16 Liao Y, Liu N, Hua X et al. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. Cell Death Dis. 8(2), e2585 (2017).Crossref, Medline, CAS, Google Scholar17 Zhu Y, Zhang Y, Sui Z, Zhang Y, Liu M, Tang H. USP14 de-ubiquitinates vimentin and miR-320a modulates USP14 and vimentin to contribute to malignancy in gastric cancer cells. Oncotarget 8(30), 48725–48736 (2017).Crossref, Medline, Google Scholar18 President and Fellows of Harvard College: WO2012012712 (2012).Google Scholar19 Proteostasis Therapeutics, Inc.: WO2013112651 (2013).Google Scholar20 Hu M, Li P, Song L et al. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 24(21), 3747–3756 (2005).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByUSP14 promotes colorectal cancer progression by targeting JNK for stabilization24 January 2023 | Cell Death & Disease, Vol. 14, No. 1The role of amyloid β in the pathological mechanism of GNE myopathy29 July 2022 | Neurological Sciences, Vol. 43, No. 11USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines20 July 2020 | The FEBS Journal, Vol. 288, No. 4Molecular Mechanisms of DUBs Regulation in Signaling and Disease20 January 2021 | International Journal of Molecular Sciences, Vol. 22, No. 3Ubiquitin-specific protease 14 promotes prostate cancer progression through deubiquitinating the transcriptional factor ATF2Biochemical and Biophysical Research Communications, Vol. 524, No. 1Emerging role of ubiquitin-specific protease 14 in oncogenesis and development of tumor: Therapeutic implicationLife Sciences, Vol. 239 Vol. 10, No. 15 Follow us on social media for the latest updates Metrics Downloaded 177 times History Received 28 April 2018 Accepted 11 May 2018 Published online 15 August 2018 Published in print August 2018 Information© 2018 Newlands PressKeywordscancerDUBsinhibitorsUSP14Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2885393419 created "2018-08-22" @default.
• W2885393419 creator A5014861208 @default.
• W2885393419 creator A5077216620 @default.
• W2885393419 date "2018-08-01" @default.
• W2885393419 modified "2023-09-23" @default.
• W2885393419 title "USP14 inhibitors as potential anticancer agents" @default.
• W2885393419 cites W2001234769 @default.
• W2885393419 cites W2012296420 @default.
• W2885393419 cites W2051458654 @default.
• W2885393419 cites W2057173428 @default.
• W2885393419 cites W2061049933 @default.
• W2885393419 cites W2101622956 @default.
• W2885393419 cites W2102657596 @default.
• W2885393419 cites W2132578269 @default.
• W2885393419 cites W2169045918 @default.
• W2885393419 cites W2285013942 @default.
• W2885393419 cites W2310322011 @default.
• W2885393419 cites W2492531936 @default.
• W2885393419 cites W2508904400 @default.
• W2885393419 cites W2583517964 @default.
• W2885393419 cites W2761249894 @default.
• W2885393419 cites W2765667919 @default.
• W2885393419 doi "https://doi.org/10.4155/fmc-2018-0150" @default.
• W2885393419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30109962" @default.
• W2885393419 hasPublicationYear "2018" @default.
• W2885393419 type Work @default.
• W2885393419 sameAs 2885393419 @default.
• W2885393419 citedByCount "8" @default.
• W2885393419 countsByYear W28853934192019 @default.
• W2885393419 countsByYear W28853934192020 @default.
• W2885393419 countsByYear W28853934192021 @default.
• W2885393419 countsByYear W28853934192022 @default.
• W2885393419 countsByYear W28853934192023 @default.
• W2885393419 crossrefType "journal-article" @default.
• W2885393419 hasAuthorship W2885393419A5014861208 @default.
• W2885393419 hasAuthorship W2885393419A5077216620 @default.
• W2885393419 hasConcept C102658986 @default.
• W2885393419 hasConcept C104317684 @default.
• W2885393419 hasConcept C137620995 @default.
• W2885393419 hasConcept C185592680 @default.
• W2885393419 hasConcept C25602115 @default.
• W2885393419 hasConcept C2779473830 @default.
• W2885393419 hasConcept C55493867 @default.
• W2885393419 hasConcept C62478195 @default.
• W2885393419 hasConceptScore W2885393419C102658986 @default.
• W2885393419 hasConceptScore W2885393419C104317684 @default.
• W2885393419 hasConceptScore W2885393419C137620995 @default.
• W2885393419 hasConceptScore W2885393419C185592680 @default.
• W2885393419 hasConceptScore W2885393419C25602115 @default.
• W2885393419 hasConceptScore W2885393419C2779473830 @default.
• W2885393419 hasConceptScore W2885393419C55493867 @default.
• W2885393419 hasConceptScore W2885393419C62478195 @default.
• W2885393419 hasIssue "15" @default.
• W2885393419 hasLocation W28853934191 @default.
• W2885393419 hasLocation W28853934192 @default.
• W2885393419 hasOpenAccess W2885393419 @default.
• W2885393419 hasPrimaryLocation W28853934191 @default.
• W2885393419 hasRelatedWork W2059292258 @default.
• W2885393419 hasRelatedWork W2157718895 @default.
• W2885393419 hasRelatedWork W2587768464 @default.
• W2885393419 hasRelatedWork W2972607243 @default.
• W2885393419 hasRelatedWork W2980383653 @default.
• W2885393419 hasRelatedWork W3030461704 @default.
• W2885393419 hasRelatedWork W3098975119 @default.
• W2885393419 hasRelatedWork W3202459660 @default.
• W2885393419 hasRelatedWork W3204423549 @default.
• W2885393419 hasRelatedWork W4307832806 @default.
• W2885393419 hasVolume "10" @default.
• W2885393419 isParatext "false" @default.
• W2885393419 isRetracted "false" @default.
• W2885393419 magId "2885393419" @default.
• W2885393419 workType "article" @default.